Please enable JavaScript to continue using this application.

Compare $AGEN vs $PRLD | Chartloom

Compare

$AGEN vs $PRLD

Agenus Inc · Prelude Therapeutics Inc

AGEN

Agenus Inc

PRLD

Prelude Therapeutics Inc

Compare $AGEN vs $PRLD

Comparing Agenus Inc and Prelude Therapeutics Inc

AGENAgenus Inc

PRLDPrelude Therapeutics Inc

AGENAgenus Inc

Market cap

$319M

P/E (TTM)

3.45x

Forward P/E (NTM)

—

Forward P/S (NTM)

3.37x

Rev growth (TTM)

30.5%

YTD performance

137.5%

52W performance

83.9%

FCF yield

-30.8%

PRLDPrelude Therapeutics Inc

Market cap

$310M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.94x

Rev growth (TTM)

—

YTD performance

42.5%

52W performance

173.9%

FCF yield

-10.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AGEN

PRLD

Detailed metrics comparison

AGEN

Agenus Inc

PRLD

Prelude Therapeutics Inc

Market Cap

AGEN$319M

PRLD$310M

Enterprise Value

AGEN$580M

PRLD$284M

Price

AGEN$7.67

PRLD$3.89

P/E Ratio

AGEN3.45x

PRLDN/A

P/S Ratio

AGEN2.41x

PRLD13.82x

EV/Sales

AGEN4.37x

PRLD12.64x

EV/EBITDA

AGEN13.66x

PRLD0.00x

P/B Ratio

AGEN110.53x

PRLD2.19x

P/FCF Ratio

AGENN/A

PRLDN/A

EV/FCF

AGEN-5.89x

PRLD-8.53x

PEG Ratio

AGENN/A

PRLDN/A

Forward P/E (NTM)

AGENN/A

PRLDN/A

Forward P/S (NTM)

AGEN3.37x

PRLD5.94x

Revenue (TTM)

AGEN$133M

PRLD$22M

Revenue Growth (YoY)

AGEN30.5%

PRLDN/A

Forward Rev Growth

AGEN-1.2%

PRLD-14.3%

Gross Margin (TTM)

AGEN99.5%

PRLD0.0%

Operating Margin (TTM)

AGEN103.2%

PRLD0.0%

EBITDA Margin (TTM)

AGEN30.6%

PRLD-293.5%

Net Margin (TTM)

AGEN69.2%

PRLD-269.7%

FCF Margin (TTM)

AGEN-74.2%

PRLD-148.3%

Net Income (TTM)

AGEN$92M

PRLD$-60M

FCF (TTM)

AGEN$-99M

PRLD$-33M

EPS (TTM)

AGEN$2.22

PRLD-$0.61

ROE (TTM)

AGEN76.6%

PRLD-7535.0%

ROA (TTM)

AGEN44.9%

PRLD-4439.0%

ROIC (TTM)

AGEN48.7%

PRLD-7535.0%

Cash

AGEN$19M

PRLD$26M

Debt

AGEN$280M

PRLD$0

Net Cash/Debt

AGEN$-261M

PRLD$26M

Current Ratio (TTM)

AGEN0.34x

PRLD4.07x

Quick Ratio (TTM)

AGEN0.33x

PRLD3.99x

Debt/Equity (TTM)

AGEN4.01x

PRLD0.00x

Debt/Assets (TTM)

AGEN0.0%

PRLD0.0%

Interest Coverage (TTM)

AGENN/A

PRLDN/A

Net Debt/EBITDA (TTM)

AGEN0.00x

PRLD0.00x

Beta

AGEN1.50

PRLD1.19

52W Performance

AGEN83.9%

PRLD173.9%

YTD Performance

AGEN137.5%

PRLD42.5%

% from 52W High

AGEN-25.6%

PRLD-43.0%

% from 52W Low

AGEN183.0%

PRLD238.3%

Asset Turnover (TTM)

AGEN0.65x

PRLD0.16x

FCF Yield (TTM)

AGEN-30.8%

PRLD-10.7%

Earnings Yield (TTM)

AGEN28.7%

PRLD-19.5%

Dividend Yield (TTM)

AGENN/A

PRLDN/A

Rule of 40

AGEN-43.8

PRLD-148.3

EV/GP/RG

AGENN/A

PRLDN/A

Ticker research

View AGEN research View PRLD research

Metric	AGEN Agenus Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$319M	$310M
Enterprise Value	$580M	$284M
Price	$7.67	$3.89
P/E Ratio	3.45x	N/A
P/S Ratio	2.41x	13.82x
EV/Sales	4.37x	12.64x
EV/EBITDA	13.66x	0.00x
P/B Ratio	110.53x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.89x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.37x	5.94x
Revenue & Growth
Revenue (TTM)	$133M	$22M
Revenue Growth (YoY)	30.5%	N/A
Forward Rev Growth	-1.2%	-14.3%
Profitability
Gross Margin (TTM)	99.5%	0.0%
Operating Margin (TTM)	103.2%	0.0%
EBITDA Margin (TTM)	30.6%	-293.5%
Net Margin (TTM)	69.2%	-269.7%
FCF Margin (TTM)	-74.2%	-148.3%
Net Income (TTM)	$92M	$-60M
FCF (TTM)	$-99M	$-33M
EPS (TTM)	$2.22	-$0.61
ROE (TTM)	76.6%	-7535.0%
ROA (TTM)	44.9%	-4439.0%
ROIC (TTM)	48.7%	-7535.0%
Financial Health
Cash	$19M	$26M
Debt	$280M	$0
Net Cash/Debt	$-261M	$26M
Current Ratio (TTM)	0.34x	4.07x
Quick Ratio (TTM)	0.33x	3.99x
Debt/Equity (TTM)	4.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.50	1.19
52W Performance	83.9%	173.9%
YTD Performance	137.5%	42.5%
% from 52W High	-25.6%	-43.0%
% from 52W Low	183.0%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.16x
FCF Yield (TTM)	-30.8%	-10.7%
Earnings Yield (TTM)	28.7%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-43.8	-148.3
EV/GP/RG	N/A	N/A
Ticker research	View AGEN research	View PRLD research

Valuation

P/E Ratio

AGEN

3.45x

P/S Ratio

AGEN

2.41x

PRLD

13.82x

EV/FCF

PRLD

-8.53x

AGEN

-5.89x

Growth & revenue

Revenue Growth TTM

AGEN

30.5%

Forward Revenue Growth

AGEN

-1.2%

PRLD

-14.3%

Profitability & performance

Gross Margin

AGEN

99.5%

PRLD

0.0%

ROE

AGEN

76.6%

PRLD

-7535.0%

FCF Yield %

PRLD

-10.7%

AGEN

-30.8%

52-Week Performance

PRLD

173.9%

AGEN

83.9%

Detailed metrics comparison

AGEN

Agenus Inc

PRLD

Prelude Therapeutics Inc

Market Cap

AGEN$319M

PRLD$310M

Enterprise Value

AGEN$580M

PRLD$284M

Price

AGEN$7.67

PRLD$3.89

P/E Ratio

AGEN3.45x

PRLDN/A

P/S Ratio

AGEN2.41x

PRLD13.82x

EV/Sales

AGEN4.37x

PRLD12.64x

EV/EBITDA

AGEN13.66x

PRLD0.00x

P/B Ratio

AGEN110.53x

PRLD2.19x

P/FCF Ratio

AGENN/A

PRLDN/A

EV/FCF

AGEN-5.89x

PRLD-8.53x

PEG Ratio

AGENN/A

PRLDN/A

Forward P/E (NTM)

AGENN/A

PRLDN/A

Forward P/S (NTM)

AGEN3.37x

PRLD5.94x

Revenue (TTM)

AGEN$133M

PRLD$22M

Revenue Growth (YoY)

AGEN30.5%

PRLDN/A

Forward Rev Growth

AGEN-1.2%

PRLD-14.3%

Gross Margin (TTM)

AGEN99.5%

PRLD0.0%

Operating Margin (TTM)

AGEN103.2%

PRLD0.0%

EBITDA Margin (TTM)

AGEN30.6%

PRLD-293.5%

Net Margin (TTM)

AGEN69.2%

PRLD-269.7%

FCF Margin (TTM)

AGEN-74.2%

PRLD-148.3%

Net Income (TTM)

AGEN$92M

PRLD$-60M

FCF (TTM)

AGEN$-99M

PRLD$-33M

EPS (TTM)

AGEN$2.22

PRLD-$0.61

ROE (TTM)

AGEN76.6%

PRLD-7535.0%

ROA (TTM)

AGEN44.9%

PRLD-4439.0%

ROIC (TTM)

AGEN48.7%

PRLD-7535.0%

Cash

AGEN$19M

PRLD$26M

Debt

AGEN$280M

PRLD$0

Net Cash/Debt

AGEN$-261M

PRLD$26M

Current Ratio (TTM)

AGEN0.34x

PRLD4.07x

Quick Ratio (TTM)

AGEN0.33x

PRLD3.99x

Debt/Equity (TTM)

AGEN4.01x

PRLD0.00x

Debt/Assets (TTM)

AGEN0.0%

PRLD0.0%

Interest Coverage (TTM)

AGENN/A

PRLDN/A

Net Debt/EBITDA (TTM)

AGEN0.00x

PRLD0.00x

Beta

AGEN1.50

PRLD1.19

52W Performance

AGEN83.9%

PRLD173.9%

YTD Performance

AGEN137.5%

PRLD42.5%

% from 52W High

AGEN-25.6%

PRLD-43.0%

% from 52W Low

AGEN183.0%

PRLD238.3%

Asset Turnover (TTM)

AGEN0.65x

PRLD0.16x

FCF Yield (TTM)

AGEN-30.8%

PRLD-10.7%

Earnings Yield (TTM)

AGEN28.7%

PRLD-19.5%

Dividend Yield (TTM)

AGENN/A

PRLDN/A

Rule of 40

AGEN-43.8

PRLD-148.3

EV/GP/RG

AGENN/A

PRLDN/A

Ticker research

View AGEN research View PRLD research

Metric	AGEN Agenus Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$319M	$310M
Enterprise Value	$580M	$284M
Price	$7.67	$3.89
P/E Ratio	3.45x	N/A
P/S Ratio	2.41x	13.82x
EV/Sales	4.37x	12.64x
EV/EBITDA	13.66x	0.00x
P/B Ratio	110.53x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.89x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.37x	5.94x
Revenue & Growth
Revenue (TTM)	$133M	$22M
Revenue Growth (YoY)	30.5%	N/A
Forward Rev Growth	-1.2%	-14.3%
Profitability
Gross Margin (TTM)	99.5%	0.0%
Operating Margin (TTM)	103.2%	0.0%
EBITDA Margin (TTM)	30.6%	-293.5%
Net Margin (TTM)	69.2%	-269.7%
FCF Margin (TTM)	-74.2%	-148.3%
Net Income (TTM)	$92M	$-60M
FCF (TTM)	$-99M	$-33M
EPS (TTM)	$2.22	-$0.61
ROE (TTM)	76.6%	-7535.0%
ROA (TTM)	44.9%	-4439.0%
ROIC (TTM)	48.7%	-7535.0%
Financial Health
Cash	$19M	$26M
Debt	$280M	$0
Net Cash/Debt	$-261M	$26M
Current Ratio (TTM)	0.34x	4.07x
Quick Ratio (TTM)	0.33x	3.99x
Debt/Equity (TTM)	4.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.50	1.19
52W Performance	83.9%	173.9%
YTD Performance	137.5%	42.5%
% from 52W High	-25.6%	-43.0%
% from 52W Low	183.0%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.16x
FCF Yield (TTM)	-30.8%	-10.7%
Earnings Yield (TTM)	28.7%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-43.8	-148.3
EV/GP/RG	N/A	N/A
Ticker research	View AGEN research	View PRLD research